NASDAQ:ARVNArvinas Stock Price, Forecast & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARVN stock has decreased by 26.7% and is now trading at $32.28. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) posted its earnings results on Tuesday, April, 28th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.01. The company had revenue of $6.24 million for the quarter, compared to the consensus estimate of $5.18 million. Arvinas had a negative net margin of 171.74% and a negative return on equity of 30.74%. View Arvinas' earnings history.

11 brokerages have issued 1 year price objectives for Arvinas' shares. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' share price to reach $57.10 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price. View analysts' price targets for Arvinas.

Media coverage about ARVN stock has been trending very positive recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arvinas earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutArvinas.

Arvinas saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,570,000 shares, a drop of 11.4% from the April 30th total of 2,900,000 shares. Based on an average trading volume of 401,000 shares, the days-to-cover ratio is currently 6.4 days. Currently, 10.1% of the company's stock are short sold. View Arvinas' Current Options Chain.

Some companies that are related to Arvinas include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), PPD (SDGR), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR), ChemoCentryx (CCXI) and Biohaven Pharmaceutical (BHVN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), ImmunoGen (IMGN), Krystal Biotech (KRYS), Protalix Biotherapeutics (PLX), Senseonics (SENS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Vaxart (VXRT).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.56%), 5AM Venture Management LLC (2.55%), Orbimed Advisors LLC (2.54%), State Street Corp (1.21%), ArrowMark Colorado Holdings LLC (0.97%) and Rock Springs Capital Management LP (0.73%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, 5AM Venture Management LLC, Ghost Tree Capital LLC, Pictet Asset Management Ltd., Spark Investment Management LLC, Citigroup Inc., Sphera Funds Management LTD., and UBS Group AG. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Sean A Cassidy, and Ventures Iii LP 5Am. View insider buying and selling activity for Arvinas.

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Federated Hermes Inc., Two Sigma Advisers LP, AQR Capital Management LLC, Rock Springs Capital Management LP, State Street Corp, Schroder Investment Management Group, and Castleark Management LLC. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon. View insider buying and selling activity for Arvinas.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $32.28.

Arvinas has a market capitalization of $1.26 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]